跳至主要内容
临床试验/NCT00003325
NCT00003325已完成3 期

Intraoperative Lymphatic Mapping in Patients With Stage I and II Squamous Carcinoma of the Vulva

Gynecologic Oncology Group143 个研究点 分布在 1 个国家目标入组 515 人开始时间: 1999年12月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
515
试验地点
143
主要终点
Predictive value of negative sentinel lymph nodes in vulvar cancer patients

研究概览

简要总结

RATIONALE: Lymphatic mapping may improve the ability to detect cancer of the vulva.

PURPOSE: This phase III trial is studying how well lymphatic mapping works in treating patients with stage I or stage II cancer of the vulva.

详细描述

OBJECTIVES:

  • Determine the negative predictive value of a negative sentinel lymph node in patients with invasive squamous cell carcinoma of the vulva.
  • Determine the location of the sentinel node in these patients.

OUTLINE: Patients receive injection(s) of isosulfan blue into the dermis at the junction of the tumor and normal vulvar skin. Once the afferent lymphatic channel and sentinel node have been identified, patients undergo unilateral or bilateral inguinal-femoral lymphadenectomy followed by resection of the primary tumor with adequate margins. Preoperative lymphoscintigraphy is also performed.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter or until recurrence.

PROJECTED ACCRUAL: A total of 40-630 patients will be accrued for this study within 2-6 years.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Predictive value of negative sentinel lymph nodes in vulvar cancer patients

时间窗: at time of surgery

次要结局

未报告次要终点

研究者

申办方类型
Network
责任方
Sponsor

研究点 (143)

Loading locations...

相似试验